New Technologies In A Therapy Of Ovarian Cancer – Part 2 of 3
The first-phase studies aren’t designed to make up one’s mind if the drugs actually work, but are instead supposed to analyze whether they’re safe. This study, funded in break up by the US National Institutes of Health, found signs of improvement in 19 out of 31 patients. All 19 developed an anti-tumor immune response. Of those, eight had no measurable plague and are on maintenance vaccine therapy.
And one of the eight, whose cancer recurred several times, has been in remission for 45 months, the study authors said. The researchers added a further step for 11 patients who responded to the vaccine healing but still had residual disease. They removed immune cells called T cells from patients’ blood, stimulated and expanded the cells in the laboratory, and then reinjected them into the patients.
Of the 11 patients, seven had unchanged disease and one had a complete response, the investigators found. Both treatments were given in conjunction with bevacizumab, a drug that controls blood vessel growth. Side goods were mild. As for cost, she believes that it will be cheaper than some existing cancer drugs that cost $75000 to $100000 for a regimen.